Presenters

Arun B. Jesudian, MD, FACG, AGAF

Weill Cornell Medicine
Associate Professor of Clinical Medicine
Director of Inpatient Liver Services

Dr. Arun Jesudian is a Transplant Hepatologist and Director of Inpatient Liver Services at New York-Presbyterian Hospital/Weill Cornell Medicine. His clinical and research focus is in Quality Improvement in the care of hospitalized patients with cirrhosis and optimal management of complications of portal hypertension. He currently serves on the AGA Quality Committee, the ACG Practice Parameters Committee, and on the editorial board of Liver Transplantation.

Dr. Jesudian earned his BA from the University of Virginia and his MD from Virginia Commonwealth University School of Medicine. He then completed residency in Internal Medicine and fellowship in Gastroenterology at New York-Presbyterian Hospital/Weill Cornell Medical College as well as advanced fellowship training in Transplant Hepatology at New York-Presbyterian Hospital/Columbia University.

Kimberly A. Brown, MD, FAST, FAASLD, AGAF

Henry Ford Health System
Chief, Division of Gastroenterology and Hepatology

Dr. Kimberly A. Brown is the Chief of Gastroenterology and Hepatology and the Associate Medical Director of the Transplant Institute at Henry Ford Hospital in Detroit. Dr. Brown received her undergraduate degree from the University of Michigan in 1981. She completed her medical degree at Wayne State University in 1985. Dr. Brown completed both her residency in internal medicine as well as her fellowship in gastroenterology at the University of Michigan in 1992 and was named chief medical resident in 1984-85.

Dr. Brown joined the Henry Ford Medical Group in 1995 as medical director of the liver transplant program and was appointed Chief of the Division of Gastroenterology and Hepatology in 2003. In addition, she served as the program director for the GI fellowship program from 2003 to 2008. She has served on the Board of Governors of the Henry Ford Medical Group for 9 years, the Henry Ford Hospital and System Network Board for 3 years, and has served on several hospital and Board of Governors committees.

Dr. Brown is a member of the American Gastroenterology Association, the American Association for the Study of Liver Disease, the American College of Gastroenterology, The European Association for the Study of Liver Disease, and the American Society of Transplantation. She is past co-chair of the Michigan Chapter of the American Liver Foundation. She has served as the treasurer of the Board of the American Society of Transplantation, and on the Executive Board for the Liver and Intestine Community of Practice for AST and is involved with several committees for the society. She is currently a member of the UNOS Liver and Intestines Committee and National Review Board for Liver Transplantation. Dr. Brown is the past Secretary of the AASLD and currently serves on the AASLD Finance Committee.

As Chief of Gastroenterology and Hepatology and past medical director of liver transplantation, Dr. Brown sees and manages patients with complex liver disease both before and after liver transplantation. In conjunction with Dr. Abouljoud, she worked to develop the leading liver transplant program in the State of Michigan. As fellowship director, she managed a fellowship program of 12 GI/liver fellows and continues to be involved in structuring and monitoring their education and academic success. She has trained over 100 fellows in the field and has published over 90 articles, 125 abstracts and 8 book chapters/reviews and is past Associate Editor for Clinical Liver Disease and current Associate Editor for Liver Transplantation. Dr. Brown is a very active clinical investigator in viral hepatitis, advanced liver disease and post liver transplant management. She is also a past award winner of the Castle Connelly National Top Doc Award for Clinical Excellence and Henry Ford Medical Group Fred Whitehouse Award for Clinical Excellence.

saab_photo.JPG

Sammy Saab, MD, MPH, FACG, AGAF, FAASLD

Medical Director, Pfleger Liver Institute
Medical Director, Adult Liver Transplant Program
Chief, Transplant Hepatology
Head, Outcomes Research in Hepatology
Professor of Medicine and Surgery
Adjunct Professor of Nursing
David Geffen School of Medicine at UCLA

Sammy Saab, MD, MPH is a Professor in the Departments of Medicine and Surgery at the David Geffen School of Medicine at UCLA (University of California Los Angeles) and an Adjunct Professor of Nursing at the UCLA School of Nursing. He is currently the Medical Director of the UCLA Adult Liver Transplant Program, Medical Director of the Pfleger Liver Institute, and the Chief of Transplant Hepatology. Dr. Saab is also the Head of Outcomes Research in Hepatology. He has been on the faculty at UCLA for over two decades.

Dr. Saab received his BS, MD, and MPH degrees from UCLA. He completed his residency in internal medicine at the University of California at San Diego Medical Center and a fellowship in gastroenterology/hepatology at the UCLA Center for Health Sciences. Dr. Saab is board certified in gastroenterology and transplant hepatology. He has received honorary fellowships from the American Gastroenterology Association (AGAF), American College of Gastroenterology (FACG) and the American Association for the Study of Liver Diseases (FAASLD).

Dr. Saab serves on many local, national, and international committees. He is on Board of Directors for several liver-oriented foundations such as the American Liver Foundation, Liver Wellness Foundation and the Chronic Liver Disease Foundation. Dr. Saab has been an investigator in multiple clinical trials and is a frequently invited speaker worldwide. Dr. Saab originated and leads a popular annual patient education seminar and is co-chair of the Annual UCLA Liver Diseases Symposium for health care professionals. He has mentored many college and medical students, as well as medical residents and fellows in gastroenterology.

Dr. Saab has published nearly 350 peer-reviewed manuscripts. He has authored numerous book chapters, editorials, and abstracts. On the editorial board of over a dozen journals, Dr. Saab is the associate editor for the Journal of Clinical Gastroenterology, Digestive Medicine Research (DMR), and Journal of Clinical and Translational Hepatology.

xifaxan-logo-blue.png
INDICATION

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults.   

IMPORTANT SAFETY INFORMATION
  • XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.
  • There is an increased systemic exposure in patients with severe (Child-Pugh Class C) hepatic impairment. Caution should be exercised when administering XIFAXAN to these patients.
  • Caution should be exercised when concomitant use of XIFAXAN and P-glycoprotein (P-gp) and/or OATPs inhibitors is needed. Concomitant administration of cyclosporine, an inhibitor of P-gp and OATPs, significantly increased the systemic exposure of rifaximin. In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase the systemic exposure to rifaximin.
  • In a clinical study, the most common adverse reactions for XIFAXAN in HE (≥10%) were peripheral edema (15%), nausea (14%), dizziness (13%), fatigue (12%), and ascites (11%).
  • INR changes have been reported in patients receiving rifaximin and warfarin concomitantly. Monitor INR and prothrombin time. Dose adjustment of warfarin may be required.
  • XIFAXAN may cause fetal harm. Advise pregnant women of the potential risk to a fetus.

To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please click here for full Prescribing Information.

Toggle icon
INDICATION

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults.   

IMPORTANT SAFETY INFORMATION
  • XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.
IMPORTANT SAFETY INFORMATION
  • XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.